Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialEurope PMCOpen access

PLOD2 gene expression in infrapatellar fat pad is correlated with fat mass in obese patients with end-stage knee osteoarthritis

Van den Langenbergh J., Bastiaansen-Jenniskens YM., van Osch GJVM., Runhaar J., Bierma-Zeinstra SMA., Soballe K.

Randomized Controlled Trial with a reported sample of 48 on Knee Osteoarthritis, Osteoarthritis, published in Osteoarthr Cartil Open (2024) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Osteoarthr Cartil Open (2024)
Reported sample size
48
Source database
Europe PMC
PMID
38694906
PMCID
PMC11061337
DOI
10.1016/j.ocarto.2024.100469
Citations
2

Abstract (original English)

Objective To investigate associations between obesity-linked systemic factors and gene expression indicative for the inflammatory and fibrotic processes in the infrapatellar fat pad (IFP), in a population of obese patients with end-stage knee osteoarthritis (KOA). Methods We collected human IFPs from 48 patients with a mean body mass index (BMI) of 35.44 ​kg/m 2 during total knee replacement procedures. These patients were part of a randomized controlled trial and met the criteria of having OA and a BMI of ≥30 ​kg/m 2 . Blood samples were collected to assess serum levels of glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and leptin. Total body composition was measured using dual-energy X-ray absorptiometry. Gene expressions of IL6, TNFA, COL1A1, IL1B, ASMA, PLOD2 in the IFP were analyzed. Results Univariate analysis resulted in a positive correlation between BMI and procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 ( PLOD2 ) expression ( r 2 ​= ​0.13). In univariate analyses of obesity-linked systemic factors and PLOD2 , significant correlations were found for lean mass ( r 2 ​= ​0.20), fat mass ( r 2 ​= ​0.20), serum cholesterol ( r 2 ​= ​0.17), serum triglycerides ( r 2 ​= ​0.19) and serum leptin ( r 2 ​= ​0.10). A multiple linear regression model indicated fat mass to be a strong predictor of PLOD2 production in the IFP ( r 2 ​= ​0.22, P ​= ​0.00

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research